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Tetracycline resistanceBackground: Antibiotic resistance of Helicobacter pylori (H. pylori) treatment is on the rise, and is affecting
the efficacy of current used therapeutic regimens.
Aim: We aimed to enhance the understanding of antimicrobial resistance rates of H. pylori strains recov-
ered from patients at Theodor Bilharz Research Institute Hospital in Egypt, as a mandatory step before
starting treatment.
Subjects and methods: Mutant genes conferring metronidazole, amoxicillin, clarithromycin, and tetracy-
cline resistance were detected in 60 H. pylori strains recovered from patients who underwent upper endo-
scopic examination. Patients were considered to be infected with H. pylori when rapid urease test and
detection of 16S rRNA in gastric biopsies recorded positive. Molecular detection of resistant genes to
metronidazole (rdx gene) and amoxicillin (pbp1A gene) was carried out by conventional PCR followed
by sequencing of PCR products. While detection of 23S rRNA gene conferring clarithromycin resistance
and detection of 16S rRNA mutation gene conferring tetracycline resistance were carried out by real-
time PCR.
Results: H. pylori resistance rates to metronidazole, and amoxicillin were 25% and 18.3% respectively.
While for clarithromycin and tetracycline, point mutations in 23S rRNA types A2142G and A2143G and
in 16S rRNA of H. pylori were assessed by real time PCR assay respectively. Resistance mutant genes were
found to be 6.7% of clarithromycin and 1.7% of tetracycline. Combined resistance rates to metronidazole
and amoxicillin was (11.6%) followed by metronidazole and clarithromycin (5%), while patterns of clar-
ithromycin and amoxicillin (1.6%), metronidazole, clarithromycin and amoxicillin (1.6%) were revealed.
Conclusion: Data concerning antimicrobial resistance genes play an important role in empiric treatment
of H. pylori infection. According to our results, H. pylori resistance to metronidazole and amoxicillin was
relatively high. Clarithromycin is still a good option for first line anti-H. pylori treatment. Combined resis-
tant strains are emerging and may have an effect on the combination therapy.
 2018 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Eradication of H. pylori does not only heal gastritis of peptic
ulcer disease, but may prevent the spread of infection and H. pylori
recurrence. Also, it may reduce the risk of development of gastric
cancer, thus reducing further costs required for the treatment of
subsequent H. pylori-associated diseases [1]. The treatment of
H. pylori infection employs a triple drug regimen using one of the
following antibiotics (amoxicillin, tetracycline or clarithromycin)
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muth salt, and combined PPI and bismuth salt with quadruple reg-
imen when triple therapy regimens have failed. In Egypt, the
standard therapy combines PPI and metronidazole, and one
antimicrobial drug, chosen from among clarithromycin and amox-
icillin [2–4].
Antibiotic resistance is a key factor in the failure of eradication
therapy and recurrence of H. pylori infection [5]. Worldwide H.
pylori antibiotic resistance towards different antibiotics is increas-
ing and it is the main factor affecting efficacy of current therapeu-
tic regimens. Prevalence of bacterial resistance varies in different
geographic areas, and it has been correlated with the widespread
use of certain antibiotics in the general population (i.e. clar-
ithromycin for respiratory infections, metronidazole for parasite
diseases and dental infections, tetracycline for respiratory and
bowel diseases, amoxicillin for streptococcal pharyngitis, urinary
tract infections [6]. In countries where the use of clarithromycin
is rare, the resistance rate is low, while in countries where its
use is wide, the resistance rate reaches 10–15%. Similarly,
metronidazole-resistance rate is much higher in developing coun-
tries (50–80%) [7]. Amoxicillin is suggested for anti-H. pylori triple
therapy in regions where metronidazole resistance is high. Univer-
sal resistance to amoxicillin is uncommon; it was detected in
14.67% [8].Tetracycline resistance has not become a great problem
yet [2].
The aim of this study was to enhance the understanding of
antimicrobial resistance rates of H. pylori strains recovered from
patients at Theodor Bilharz Research Institute TBRI Hospital in
Egypt, as a mandatory step before starting treatment.2. Subjects and methods
2.1. Patients and clinical specimens
From December 2015 to January 2017, 60 H. pylori infected
patients who underwent upper endoscopy for various dyspeptic
symptoms at Endoscopy Unit, TBRI Hospital were enrolled in this
study. The sample size was calculated by Epi Info program (version
6.0) at 95%Confidence Limit, Power of the Test is 80% and Alpha
Setat 0.05 (Type Error). None of the patients had received non-
steroidal anti-inflammatory drugs, as well as antibiotics, H2 recep-
tors antagonists or proton pump inhibitors in the past four weeks
prior to the study. During upper gastrointestinal endoscopy, four
antral biopsies were obtained from each patient. One biopsy was
tested for rapid urease test, that was performed using rapid urease
liquid test kit (Bussero, Milan, Italy) and the other three gastric
biopsies were stored in sterile physiological saline and kept at
70 C until processed. DNA extraction used directly for detection
of 16S rRNA, rdxA, Pbp1, 23S rRNA and 16S rRNA mutation genes
using PCR assays. A patient was considered to be infected with H.
pylori when he had positive rapid urease test and confirmed by
detection of 16S rRNA in gastric biopsy specimens. This work was
supported by Theodor Bilharz Research Institute (TBRI) as a part
of an ongoing internal project No. 93 T. The protocol was approved
by TBRI institutional review board (FWA00010609) and all patients
provided a written informed consent. The work has been carried
out in accordance with the Code of Ethics of the World Medical
Association (Declaration of Helsinki) for Experiments in Humans.2.2. DNA extraction from gastric biopsy specimens and PCR assays
Genomic DNA was extracted from gastric biopsy specimens
using QIAamp tissue kit (QIAamp DNA Mini Kit from QIAGEN,
USA), following manufacturer guidelines.2.2.1. Detection of H. Pylori 16S rRNA gene
Conventional PCR assay was performed in a volume of 50ul
with approximately 5 mg of extracted DNA, 200 mM (each) dNTPs,
25 pmol for each primer, 1.5 mM Magnesium Chloride and 1unit
(U) of Taq polymerase (Gotaq Flexi DNA, M8305, Promega, Inc.,
USA) in PCR buffer using primers according to[9]. The sequences
of forward (F) and reverse (R) primers are: F 50-CTG GAG AGA
CTA AGC CCT CC-30 and R 50-ATT ACT GAC GCT GAT TGT GC-30.
An initial denaturation at 95 C for 5 min followed by 35cycles
of denaturation at 95 C for 1 min, annealing at 60 C for 1 min
and 72 C for 1min. This was followed by a final extension at 72 C
for 5 min. The size of the expected amplicon was 110 bp.
2.2.2. Detection of rdxA gene conferring metronidazole resistance
Conventional polymerase chain reaction (PCR) assay was per-
formed in a volume of 50ul with approximately 2.5 mg of the
extracted DNA, 200 mM (each) dNTPs, 2.5 mM Magnesium Chloride
and 0.25 U of Taq polymerase (Promega, USA) in PCR buffer using
25 pmol primers. Primer sequences according to (Debets-
Ossenkopp et al. [10] are: F: 50-AAT TTG AGC ATG GGG CAG A-30
and R: 50-GAA ACG CTT GAA AAC ACC CCT-30.
Amplification was carried using; denaturing temperature at 95 C
for 5 min, followed by 40 cycles denaturing temperature at 94 C
for 30 s, an annealing temperature at 55 C for 30 s and an elonga-
tion temperature at 72 C for 1 min. This was followed by a final
extension of 72 C for 10 min. The size of expected amplicon was
581 bp.
2.2.3. Detection of Pbp1A gene conferring amoxicillin resistance
Conventional PCR assay was performed in a volume 50ul, with
approximately 1 mg of extracted DNA, 200 mM (each) dNTPs,
(Table: 3), 0.5u of Pfu DNA polymerase (Thermo, USA) in PCR 5
ml Pfu buffer with Magnesium Sulphate and 25 pmol primer [12].
The sequences of the F and R primers are: F 5-GCG ACA ATA AGA
GTG GCA-30 and R 50-TGC GAA CAC CCT TTT AAA T-30.
The following cycling parameters were used; denaturing tem-
perature of 95 C for 3 min, followed by 35 cycles of denaturing
temperature of 95 C for 1 min, an annealing temperature of 54 C
for 1 min and an elongation temperature of 72 C for 5 min and
final extension at72C for 10 min. The size of expected amplicon
was 2300 bp.
Each PCR product was separated on 2% agarose gel with ethid-
ium bromide, and 100 bp ladder used as DNA molecular weight
standard. In each PCR assay, a negative control (lacking DNA)
was included. PCR products were analyzed under UV light [11].
2.2.4. Sequencing of DNA fragments of rdxA and Pbp1A genes
Genomic DNA fragments were purified from agarose gel using
purification kit (Thermo Scientific GeneJET Gel Extraction Kit,
USA) according to the manufacturer’s instructions. DNA sequenc-
ing was made by Sanger sequencing method following the manu-
facturer’s instructions. Based on the selective incorporation of
chain-terminating dideoxynucleotides by DNA polymerase during
in vitro DNA replication [12].
To compare between wild and mutant genes, alignment was
made online at site http://www.ebi.ac.uk/Tools/msa/clustalw2/.
2.2.5. Detection of 23S rRNA gene conferring clarithromycin resistance
The real-time (TaqMan, USA) PCR assay was performed in a vol-
ume of 25ul, with approximately 10 ng of purified DNA, 12.5 ml
universal PCR master mix (ABI, USA), 36 ul of each primer, 8 mM
of FAM- and VIC-labeled TaqMan MGB probes [13].
Primers and probes sequences according to Lins et al. [14] are:
F: 50 TCA GTG AAA TTG TAG TGG AGG TGA AAA-30
R: 50 CAG TGC TAA GTT GTA GTA AAG GTC CA-30
VIC
Table 1
Distribution of antimicrobial resistance of H. pylori strains in gastric biopsy specimens
from 60H. pylori infected patients.
Rate of resistance H. pylori infected patients (n = 60)
Number %
Metronidazole
Detected mutation 15 25.0
Amoxicillin







Fig. 2. DNA sequence analysis of PCR product of metronidazole rdxA gene from
gastric biopsy. Diagram showed the wild type (ACA) substituted by the mutant type
(ATA).
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FAM
AAG ACG GGA AGA CC (for mutation: 23S rRNA A2142G)
FAM
CAA GAC GGA GAG ACC (for mutation: 23S rRNA A2143G)
Two point mutations of H. pylori 23S rRNA (A2142G and A2143G)
were assayed. The conditions of Real-time PCR amplification were
95 C for 10 min and 40 cycles of 92 C for 15 s and 60 C for 1 min.
The result of the analysis yields two major clusters corresponding
to the three genotypic constituents: (i) wild-type homozygous (ii)
mutated type homozygous and (iii) heterozygous.
2.2.6. Detection of 16S rRNA mutation gene conferring tetracycline
resistance
The real-time (TaqMan) PCR assay was performed in a volume
of 25ul, with approximately 1 ug of extracted DNA, 12.5 ul univer-
sal PCR master mix (Applied Bio-systems ABI, USA), 5 pmol of each
primer and 2.5 pmol of probe [15].
The sequence of the F and R primers are: F 50-CGG TCG CAA GAT
TAA AAC-30 and R 50-GCG GAT TCT CTC AAT GTC-30. The Probe
sequence: 5-FAM-GCA TGT GGT TTA ATT CGA AGA TAC AC-
TAMRA-3
Point mutations of H. pylori 16S rRNA gene were assessed. The
assay was run on real time PCR ABI step one using the following
cycling conditions: The reaction was held for 10 min at a denatur-
ing temperature of 95 C, followed by 50 cycles of denaturing tem-
perature of 95 C for 10 s, an annealing temperature between 50 C
for 2 s and 55 C for 1 s and extension temperature of 72 C for 30 s.
This was followed by a single probe melting cycle: 95 C (ramp
rate, 20 C /s), 45 C (ramp rate, 20 C /s) and 80 C (ramp rate,
0.5 C/s).
The real time PCR assay produced a peak at a melting tempera-
ture: wild-type Tm of 63 C and mutation point Tm of 58 C.
3. Results
A total of 60 H. pylori infected patients were diagnosed by rapid
urease test, and confirmed by detection of 16S rRNA gene in gastric
biopsy (amplicon was detected at 110 bp) were enrolled in this
study (Fig. 1). Forty patients (66.7%) were males and 20 patients
(33.3%) were females. The patients’ ages ranged between 17 and
76 years (49.93 ± 14.28 years), male/female ratio was 2:1.
Detection of the presence of mutant resistant genes conferring
antimicrobial resistance for metronidazole (rdxA genes) was 25%,
and for amoxicillin (pbp1A), it was 18.3%. Both of rdxA and pbp1A
genes were detected by conventional PCR followed by sequencing
(Table 1, Figs. 2 and 3)
Gene mutation in clarithromycin and tetracycline were tested
by Real Time PCR. Resistance gene 23S rRNA mutation typeFig. 1. Agarose gel electrophoresis of PCR products of H. pylori 16S rRNA from gastric b
weight marker (ladder 50 bp). Lane N negative control.A2143G was detected in (6.7%) regarding clarithromycin while
tetracycline showed only one strain (1.7%) having 16S rRNA gene
mutation (Table 1 Fig. 4).iopsy. The 110 bp fragment was detected in samples 1-5(Lanes 1-5). M: molecular
Fig. 3. Sequence analysis of PCR products of amoxicillin pbp1A positive gene from
gastric biopsy. Diagram showed the wild type (GCG) substituted by the mutant type
(CGC).
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was most frequently found, followed by metronidazole and clar-
ithromycin (5%), while patterns of clarithromycin and amoxicillin,
metronidazole, clarithromycin and amoxicillin were both 1.6%
(Table 2).Fig. 4. Melting curve shows detection of 16S rRNA mutation gene of tetracycline resistan
58 C.4. Statistical analysis
Results are expressed as number (%). Statistical Package for
Social Sciences (SPSS) computer program (version 19 windows)
was used for data analysis. P value 0.05 was considered signifi-
cant and <0.01 was considered highly significant.5. Discussion
H. pylori infection is considered as one of the most frequent bac-
terial infections of the digestive system in the world [7]. H. pylori
management in the clinical practice remains a challenge for the
physicians. The choice of appropriate antibiotics is crucial in the
success of treatment and recovery from H. pylori-related diseases.
There are strong data showing that eradication of H. pylori infec-
tion reduces the risk of peptic ulcers, dyspepsia, and likely gastric
cancer, if treated early in its natural history. However, the relative
risk reduction of each complication varies [16].
Usually, the disease has chronic features unless it is treated by
the combination of two proper antimicrobials; clarithromycin and
metronidazole or amoxicillin, with proton-pump inhibitor or H2
receptor antagonist [17].
The current treatment of H. pylori is empirical. Therefore, the
goal in designing a treatment regimen should focus on a strategy
which results in a cure rate approaching 100% [18]. Eradication
failure is concerning at the present time, it is due to a pre-
existing antimicrobial resistant H. pylori strain or emergence of a
new resistant strain from a susceptible ancestor. As reported
worldwide, the successful eradication attempts are inversely corre-
lated with antimicrobial resistance rates [19–21].
The main antimicrobial resistance mechanism is point muta-
tions [22]. Real-time PCR has been used to successfully determinece from gastric biopsy. Diagram shows wild type at Tm 63 C and mutant type at Tm
Table 2
Resistance rates of H. pylori to combined therapeutic agents in 60 patients infected
with H. pylori.
Combined rate of resistance H. pylori infected
patients (n = 60)
Number %
Metronidazole and Amoxicillin 7 11.6
Metronidazole and Clarithromycin 3 5
Clarithromycin and Amoxicillin 1 1.6
Metronidazole, Clarithromycin and Amoxicillin 1 1.6
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of PCR is the potential to gather complete antimicrobial resistance
data in patients infected with multiple strains of H. pylori.
Among the studied H. pylori gastric biopsy specimens, we
reported considerable resistance against metronidazole (25%) and
amoxicillin (18.3%) using conventional PCR assay followed by
sequencing of DNA fragments of rdxA and Pbp1A genes respec-
tively; and resistance rate to clarithromycin (6.7%) and little resis-
tance to tetracycline using real time PCR for detection of 23S rRNA
and 16S rRNA mutation respectively.
The prevalence of bacterial resistance varies in different geo-
graphic areas and appears to be increasing with time in many
countries. It could be related to drug consumption, unregulated
and extensive use of antibiotics [24]. Worldwide studies from Afri-
can countries, suggested that H. pylori antimicrobial resistance
rates is 17.2% for clarithromycin, 26.7% for metronidazole, 11.2%
for amoxicillin and 16.2% for tetracycline [25,26].
Metronidazole is used as an alternative to clarithromycin and
amoxicillin when a patient has an allergy or resistance to these
two drugs [27]. We could detect its rdxA gene mutation in 25% of
the studied H. pylori strains. Such resistance rate favors its use in
first line therapy. Our result was comparable with that from Eng-
land [28]; higher than that from the United States [29]; lower than
reports from Tunisia (51.3%) [30] and Turkey (73%) [31]. Two pre-
vious Egyptian studies showed wide variation in frequencies of
metronidazole resistance rates; Zaki et al. [26] suggested lower
rate (12.8%) of resistance to metronidazole, while Fathi et al.,
[32] reported that only 25% of isolates were negative for rdxA gene
by PCR, although100% of cases were phenotypically resistant to
metronidazole by disc diffusion and E-test methods. The high resis-
tance rate in the previous study maybe due to its use for gyneco-
logical, dental and parasitic related infectious diseases.
The prevalence of amoxicillin and tetracycline resistant rates
has fortunately remained low worldwide [33]. Amoxicillin is used
in combination with standard H. pylori therapy, the pbp1A gene
associated with amoxicillin resistance among the studied H. pylori
strains was detected in 18.3%, which was as good as that obtained
by a previous Egyptian study [26], and a study in South East Asia by
Kumala and Rani [34]. Resistance to amoxicillin has been shown to
be negligible (0 to <2%) in European countries, such as Germany
and the Netherlands [35,36]. On the other hand, H. pylori resistance
rates to amoxicillin were 100%, 38%, and 32,8% in Nigeria [37],
India [38] and Brazil [39] respectively. However, it has been sug-
gested that H. pylori resistance to amoxicillin does not reduce
treatment efficacy [40].
In the current study, the mutation sites of 16S rRNA gene associ-
ated with tetracycline resistance were detected in 1.7% of H. pylori
strains. The present data werematched with those recorded by Per-
etz et al. [7] and Ontsira et al. [41] who found that tetracycline resis-
tance was seen in 2.3% and 2.5%; respectively. Comparable results
had been reported by Shiota et al. [29] who found tetracycline resis-
tance in 0.74% of the isolates. Rasheed et al. [31] could not detect
neither amoxicillin nor tetracycline resistance in their study.
Since amoxicillin and tetracycline resistance are rare worldwide
and bacterial resistance to metronidazole does not significantlyaffect eradication rates [42], the main concern is about clar-
ithromycin which is used as an essential component of standard
triple therapy for H. pylori [27].
The clarithromycin resistance is the major problem of treat-
ment failure of H. pylori infection in many countries. Prevalence
of primary clarithromycin resistance is increasing worldwide.
Three main point mutations in 23S rRNA at A2143G, A2142G,
A2142C of domain V are responsible for more than 90% of clar-
ithromycin resistance cases, and the most common is A-G transi-
tions at position2143 (A2143G) [43].
In the current study mutation site of 23S rRNA associated with
clarithromycin resistance was determined at A2143G in 6.7% of H.
pylori gastric biopsieswhichwas slightly higher thanprevious Egyp-
tian study (4%) by Sherif et al. [3] and it was comparable with Elviss
et al. [44] in North Wales where the mutation site (A2143G) is the
most common point of mutation site among the Italian population
as it is associatedwith a higher eradication failure rate [45]. In areas
of low resistance, treatments containing clarithromycin are recom-
mended as a first-line empirical treatment [46]. None of ourH. pylori
strainshadpointmutation inA2142G. Acosta et al. [47] reported that
the A2143G mutation was more frequent than the other mutation
A2142G, and both were the most frequent mutations.
The clarithromycin resistance of H. pylori was significantly dif-
ferent between three geographical areas (17.5% in Europe, 18.9%
in Asia and 29.3% in America). Among Asian countries, the high
resistance rate of 84.9% and 40.7% was detected in China and Japan,
respectively [25,48]. The variability of clarithromycin resistance
seen in different regions emphasizes the need to examine resis-
tance rates in each geographic area to better guide treatment reg-
imens [49].
In the current study, the overall combined resistance rates were
11.6% for metronidazole and amoxicillin, 5% for metronidazole and
clarithromycin and 1.6% for metronidazole, amoxicillin and clar-
ithromycin. Elviss et al. [44] showed combined resistance for
metronidazole and clarithromycin in 3.5% of their studied cases.
A recent study by Phan et al. [50] showed that combined metron-
idazole and clarithromycin resistance was present in 15.2% and the
triple resistance was present in 15.2%. A study by Picoli et al. [51]
found that combined resistance to clarithromycin and amoxicillin
was present in 18% of cases. Boltin et al. [52] showed that dual
resistance to clarithromycin and metronidazole was seen in
39.9% which is much higher than our data.
Although clarithromycin resistance rate has reached more than
20% in many countries and regions worldwide, of which consensus
guidelines recommended its removal from empirical triple therapy
commonly used as a first line of treatment of H. pylori [53], our
results suggested that the use of such therapy is still possible. Mon-
itoring of anti-microbial susceptibility to H. pylori can be achieved
throughmolecular methodswhich provide an attractive alternative
to conventional culture methods. The use of molecular methods
may allow the establishment of designed plans of H. pylori antimi-
crobial therapy that allows successful eradication and reduction of
H. pylori associated disease and complications [54].
Although our data nearly have not crossed the 15–20% thresh-
old for H. pylori antimicrobial resistance, there is a critical need
to determine the current rates of such resistance. Such a determi-
nation would not only facilitate the selection of appropriate treat-
ment regimens but also serve as a potential basis for transitioning
to individualized analysis of antibiotic resistance prior to definitive
treatment [49].6. Conclusion
In conclusion, data concerning antimicrobial resistance genes
play an important role in empiric treatment of H. pylori infection.
422 M. Diab et al. / The Egyptian Journal of Medical Human Genetics 19 (2018) 417–423According to our results, H. pylori resistance to metronidazole and
amoxicillin was relatively high. Clarithromycin is still a good
option for first line anti-H. pylori treatment. Combined resistant
strains are emerging and may have an effect on the combination
therapy. In addition, constructing of an H. pylori resistance map
using actual data from different regions of the world is crucial
for the development. of appropriate eradication treatment alterna-
tives. Without new treatment alternatives, we believe that H. pylori
eradication may become an important problem in our country in
the future. The increasing antimicrobial resistance of H. pylori
and the emergence of multidrug-resistant strains are important
issues that require the identification of new, more effective treat-
ment alternatives.References
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